AGIOS PHARMACEUTICALS, INC.·4

Mar 3, 4:13 PM ET

Milanova Tsveta 4

4 · AGIOS PHARMACEUTICALS, INC. · Filed Mar 3, 2026

Insider Transaction Report

Form 4
Period: 2026-03-01
Milanova Tsveta
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common stock

    2026-03-02+5,66640,459 total
  • Sale

    Common stock

    [F1]
    2026-03-02$28.96/sh1,681$48,68238,778 total
  • Exercise/Conversion

    Common stock

    2026-03-02+4,00042,778 total
  • Sale

    Common stock

    [F2]
    2026-03-02$28.96/sh1,187$34,37641,591 total
  • Award

    Restricted stock units

    [F3][F4]
    2026-03-01+14,00014,000 total
    Common stock (14,000 underlying)
  • Award

    Stock options (right to buy)

    [F5]
    2026-03-01+52,00052,000 total
    Exercise: $30.23Exp: 2036-03-01Common stock (52,000 underlying)
  • Exercise/Conversion

    Restricted stock units

    [F3][F6]
    2026-03-025,6665,667 total
    Common stock (5,666 underlying)
  • Exercise/Conversion

    Restricted stock units

    [F3][F7]
    2026-03-024,0008,000 total
    Common stock (4,000 underlying)
Footnotes (7)
  • [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
  • [F2]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F4]The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F5]This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.
  • [F6]The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F7]The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
Signature
/s/ William Cook, as Attorney in Fact for Tsveta Milanova|2026-03-03

Documents

1 file
  • 4
    wk-form4_1772572436.xmlPrimary

    FORM 4